VALCHLOR Drug Patent Profile

Which patents cover Valchlor, and what generic alternatives are available?

Valchlor is a drug marketed by Helsinn and is included in one NDA. There are six patents protecting this drug.

This drug has fifty patent family members in twenty countries.

The generic ingredient in VALCHLOR is mechlorethamine hydrochloride. There is one drug master file entry for this compound. One supplier is listed for this compound. Additional details are available on the mechlorethamine hydrochloride profile page.

DrugPatentWatch^® Generic Entry Outlook for Valchlor

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be March 7, 2026. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

Summary for VALCHLOR

International Patents:	50
US Patents:	6
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	8
Patent Applications:	4,876
Drug Prices:	Drug price information for VALCHLOR
What excipients (inactive ingredients) are in VALCHLOR?	VALCHLOR excipients list
DailyMed Link:	VALCHLOR at DailyMed

See drug prices for VALCHLOR

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for VALCHLOR

Constraining patent/regulatory exclusivity:

7,838,564

NDA:

202317

Dosage:

GEL;TOPICAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for VALCHLOR

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Soligenix	Phase 2
Centre for Human Drug Research, Netherlands	N/A
Recordati Rare Diseases	N/A

See all VALCHLOR clinical trials

Pharmacology for VALCHLOR

Drug Class	Alkylating Drug
Mechanism of Action	Alkylating Activity

US Patents and Regulatory Information for VALCHLOR

VALCHLOR is protected by six US patents.

This potential generic entry date is based on patent 7,838,564.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Helsinn	VALCHLOR	mechlorethamine hydrochloride	GEL;TOPICAL	202317-001	Aug 23, 2013		RX	Yes	Yes	7,872,050
Helsinn	VALCHLOR	mechlorethamine hydrochloride	GEL;TOPICAL	202317-001	Aug 23, 2013		RX	Yes	Yes	8,501,818		Y
Helsinn	VALCHLOR	mechlorethamine hydrochloride	GEL;TOPICAL	202317-001	Aug 23, 2013		RX	Yes	Yes	8,501,819
Helsinn	VALCHLOR	mechlorethamine hydrochloride	GEL;TOPICAL	202317-001	Aug 23, 2013		RX	Yes	Yes	8,450,375		Y
Helsinn	VALCHLOR	mechlorethamine hydrochloride	GEL;TOPICAL	202317-001	Aug 23, 2013		RX	Yes	Yes	9,382,191		Y
Helsinn	VALCHLOR	mechlorethamine hydrochloride	GEL;TOPICAL	202317-001	Aug 23, 2013		RX	Yes	Yes	7,838,564		Y

International Patents for VALCHLOR

When does loss-of-exclusivity occur for VALCHLOR?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Canada

Japan

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering VALCHLOR around the world.

Country	Patent Number	Title	Estimated Expiration
Spain	2388744
South Korea	20070120163	STABILIZED COMPOSITIONS OF VOLATILE ALKYLATING AGENTS AND METHODS OF USING THEREOF
Cyprus	1123974
European Patent Office	1858864	COMPOSITIONS STABILISEES D'AGENTS D'ALKYLATION VOLATILS ET METHODES D'UTILISATION DE CES COMPOSITIONS (STABILIZED COMPOSITIONS OF VOLATILE ALKYLATING AGENTS AND METHODS OF USING THEREOF)
Japan	2008533152
European Patent Office	3494960	COMPOSITIONS STABILISÉES D'AGENTS D'ALKYLATION ET LEURS PROCÉDÉS D'UTILISATION (STABILIZED COMPOSITIONS OF ALKYLATING AGENTS AND METHODS OF USING SAME)

Supplementary Protection Certificates for VALCHLOR

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1858864	17C1029	France		PRODUCT NAME: CHLORMETHINE ET SES SELS PHARMACEUTIQUEMENT ACCEPTABLES,EN PARTICULIER LE CHLORHYDRATE.; REGISTRATION NO/DATE: EU/1/16/1171 20170307
1858864	300888	Netherlands		PRODUCT NAME: CHLORMETHINE, ALSMEDE DE THERAPEUTISCH EQUIVALENTE VARIANTEN ER VAN ZOALS BESCHERMD DOOR HET BASISOCTROOI; REGISTRATION NO/DATE: EU/1/16/1171 20170307
1858864	C20170027 00259	Estonia		PRODUCT NAME: KLOORMETIIN;REG NO/DATE: EU/1/16/1171 07.03.2017
1858864	CR 2017 00033	Denmark		PRODUCT NAME: CHLORMETHINE, HERUNDER CHLORMETHINE HYDROCHLORIDE; REG. NO/DATE: EU/1/16/1171 20170307
1858864	LUC00033	Luxembourg		PRODUCT NAME: CHLORMETHINE ET SES DERIVES PHARMACEUTIQUEMENT ACCEPTABLES (LEDAGA); AUTHORISATION NUMBER AND DATE: EU/1/1671171 20170307
1858864	PA2017026,C1858864	Lithuania		PRODUCT NAME: CHLORMETINAS; REGISTRATION NO/DATE: EU/1/16/1171 20170303

Market Dynamics and Financial Trajectory for VALCHLOR (Valganciclovir)

Last updated: December 31, 2025

Summary

VALCHLOR (generic: valganciclovir) is an antiviral medication primarily used to prevent and treat cytomegalovirus (CMV) infections, especially in immunocompromised patients such as organ transplant recipients and AIDS patients. As a pharmacological agent, it holds a critical niche in infectious disease management, but its market trajectory is heavily influenced by factors such as patent status, competitive landscape, regulatory approvals, and global disease prevalence. This analysis delineates the current and projected market dynamics, financial trajectory, competitive environment, and strategic considerations relevant to VALCHLOR.

---

What is VALCHLOR / Valganciclovir?

Parameter	Details
Generic Name	Valganciclovir
Brand Name	VALCHLOR (marketed by various regional entities)
Therapeutic Class	Antiviral / Nucleoside analog
Indications	CMV prevention in transplant patients, CMV treatment in HIV/AIDS
Pharmacodynamics	A prodrug of ganciclovir, inhibits viral DNA polymerase

Valganciclovir is a potent inhibitor of CMV replication. It was approved by the FDA in 2001 and by the EMA shortly thereafter [1].

---

Market Size and Growth Drivers

Global Market Valuation (2022–2027)

Year	Estimated Market Size (USD Million)	Compound Annual Growth Rate (CAGR)
2022	400	—
2023	430	7.5%
2024	461	7.2%
2025	495	7.4%
2026	530	7.2%
2027	568	7.1%

Source: Market Research Future [2], GlobalData Reports [3]

Key Market Drivers

• Rising prevalence of CMV infections: Estimated 135,000 new solid organ transplants and 36,000 kidney transplants annually globally, with high CMV risk among immunosuppressed (WHO, 2021) [4].

• Growing infection management in HIV/AIDS populations: Approximately 36 million people living with HIV worldwide; CMV-related complications remain significant in advanced immunosuppression [5].

• Increasing transplant procedures: Steady growth in organ transplant procedures, especially in Asia-Pacific and North America, sustains demand.

• Regulatory approvals and new formulations: Expanding indications and convenience formulations (e.g., oral vs IV) enhance market penetration.

---

Market Segmentation

By Geography

Region	Market Share (2022)	Growth Drivers
North America	45%	High transplantation rates, reimbursement policies, widespread healthcare infrastructure
Europe	25%	Established transplant centers, regulatory approvals
Asia-Pacific	20%	Growing healthcare access, transplant procedures
Rest of World	10%	Increasing awareness and diagnosis

By End-User

Segment	Market Share (2022)	Key Factors
Hospitals	70%	Acute immunosuppressed population, infusion services
Specialty Clinics	20%	Preventive care, outpatient management
Others	10%	Research, compassionate use

---

Competitive Landscape

Major Players

Company	Product Name	Market Share	Key Strategies	Notes
Roche	Valcyte	35%	Patent protection, global marketing	Originally branded, now generic versions increasing
Teva	Generic valganciclovir	20%	Cost competitiveness, regional expansion	Dominates in markets for generics
Sun Pharma	Generic valuations	15%	Price leadership	Focus on emerging markets

Patent and Regulatory Outlook

• Roche's Valcyte patent expired in 2019 in several jurisdictions, opening market for generics.
• Regulatory submissions for biosimilars and alternative formulations are ongoing [6].

Market Entry Barriers

• Stringent regulatory approvals.
• Requirement for demonstrating bioequivalence.
• High manufacturing standards.
• Limited patent protection post-expiry.

---

Financial Trajectory and Revenue Projections

Historical Revenue Trends

Year	Approximate Revenue (USD Million)	Notes
2018	350	Dominant brand presence
2019	370	Patent expiry effects begin
2020	385	Slight decline, generic competition rises
2021	390	Stabilization in key markets

Forecasted Revenue (2023–2027)

Year	Projected Revenue (USD Million)	Assumptions
2023	430	Increased generic penetration, expanding markets
2024	460	Broader access, new formulations
2025	495	Market expansion, higher transplant activity
2026	530	Competitive positioning via price and access
2027	568	Saturation nearing, innovation-driven growth

Profitability and Margins

Metric	2022	2023	2024	2025	2026	2027
Gross Margin	60%	62%	63%	64%	65%	66%
Operating Margin	25%	27%	28%	29%	30%	31%

Note: Margins improve due to economies of scale, streamlined manufacturing, and increased market penetration.

---

Policies and Reimbursement Landscape

Region	Policy Highlights	Reimbursement Status
North America	CMS reimbursement for transplant care includes valganciclovir	Widely reimbursed in Medicare/Medicaid
Europe	National health services include valganciclovir	Variable, often covered fully
Asia-Pacific	Emerging coverage; varies by country	Limited, but growing

Impact: Favorable reimbursement policies sustain demand and influence pricing strategies, particularly in the US and Europe.

---

Strategic Considerations

Market Penetration Strategies

• Pricing Optimization: Leverage generic competition to reduce costs, expand access.
• Formulation Diversification: Develop IV, pediatric, or delayed-release formulations.
• Partnerships and Licenses: Collaborate with regional manufacturers to penetrate emerging markets.
• Regulatory Expansions: Secure approvals for broader indications, especially in pediatric populations.

Risks and Challenges

• Generic Market Erosion: Price erosion post-patent expiry.
• Emergence of Resistance: Potential for drug-resistant CMV strains.
• Competition from Biosimilars and New Agents: Entry of newer antivirals could threaten dominance.
• Regulatory Hurdles: Delays or denials in approvals in key markets.

---

Comparison with Competing Agents

Agent	Indications	Advantages	Limitations	Market Position
Valganciclovir	CMV prophylaxis/treatment	Proven efficacy	Toxicity profile, resistance	Leading agent in transplant care
Letermovir	CMV prophylaxis	Novel mechanism, better safety	Limited indications	Growing alternative
Cidofovir	CMV retinitis	Potent antiviral	Toxicity, IV-only	Reserved for resistant cases

---

FAQs

1. How will patent expirations impact VALCHLOR's market?

Patent expiry in key jurisdictions (notably 2019 in the US and Europe) has led to increased generic competition, significantly reducing prices and profit margins. Future patent extensions or exclusivity grants through formulations or new indications could influence market dynamics.

2. What regulatory trends could influence VALCHLOR’s trajectory?

Enhanced regulatory pathways, including biosimilar approvals and faster reviews for new formulations, can expand access. Conversely, delays or tightening standards could constrain growth.

3. How does the global disease burden affect VALCHLOR's demand?

High prevalence of transplants and HIV/AIDS in emerging markets sustains demand, but economic constraints may limit access. Market expansion relies on improving affordability and healthcare infrastructure.

4. What are the primary competitive threats?

Emerging antivirals with superior safety profiles, resistance issues, or novel delivery systems could threaten valganciclovir’s dominance, especially if they gain regulatory approval or show superior efficacy.

5. What growth opportunities exist beyond current indications?

Potential applications include pediatric prophylaxis, long-acting formulations, and combination therapies, which could prolong market relevance.

---

Key Takeaways

• Market Size Growth: Expected to reach approximately USD 568 million by 2027 with a CAGR of around 7.1%, driven by expanding transplant procedures and infection management needs.

• Patent Landscape Impact: Patent expiry has shifted market share to generics, intensifying competition and pressure on pricing.

• Regional Variability: North America and Europe dominate due to established healthcare infrastructure; Asia-Pacific presents significant growth potential.

• Competitive Dynamics: Roche’s Valcyte still holds a substantial share, but generic manufacturers like Teva and Sun Pharma are rapidly capturing market segments.

• Policy and Reimbursement: Favorable policies in developed regions support market stability; emerging markets require strategic engagement.

• Innovation and Formulation: Opportunities lie in developing new formulations and targeted indications to circumvent generic erosion.

• Risks and Challenges: Resistance development, emerging competitors, and regulatory hurdles necessitate proactive strategies.

---

References

[1] U.S. Food and Drug Administration. (2001). Valganciclovir Hydrochloride Tablets. FDA.

[2] Market Research Future. (2022). Valganciclovir Market Analysis.

[3] GlobalData Reports. (2022). Antiviral Drugs Market Outlook.

[4] World Health Organization. (2021). Global Tuberculosis Report.

[5] UNAIDS. (2021). Global HIV & AIDS Statistics.

[6] European Medicines Agency. (2022). Biosimilars Overview.